Switch theme
Sign up to access all valuation multiples
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
1993
307
LTM Revenue $62.6M
LTM EBITDA $0.2M
$35.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BRAIN Biotech has a last 12-month revenue (LTM) of $62.6M and a last 12-month EBITDA of $0.2M.
In the most recent fiscal year, BRAIN Biotech achieved revenue of $61.4M and an EBITDA of -$4.7M.
BRAIN Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BRAIN Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $62.6M | XXX | $61.4M | XXX | XXX | XXX |
| Gross Profit | $38.0M | XXX | $34.1M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $0.2M | XXX | -$4.7M | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -8% | XXX | XXX | XXX |
| EBIT | -$6.2M | XXX | -$10.3M | XXX | XXX | XXX |
| EBIT Margin | -10% | XXX | -17% | XXX | XXX | XXX |
| Net Profit | -$9.2M | XXX | -$12.5M | XXX | XXX | XXX |
| Net Margin | -15% | XXX | -20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BRAIN Biotech's stock price is EUR 2 (or $2).
BRAIN Biotech has current market cap of EUR 45.9M (or $51.5M), and EV of EUR 31.4M (or $35.3M).
See BRAIN Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.3M | $51.5M | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BRAIN Biotech has market cap of $51.5M and EV of $35.3M.
BRAIN Biotech's trades at 0.6x EV/Revenue multiple, and -10.7x EV/EBITDA.
Equity research analysts estimate BRAIN Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BRAIN Biotech has a P/E ratio of -5.6x.
See valuation multiples for BRAIN Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $51.5M | XXX | $51.5M | XXX | XXX | XXX |
| EV (current) | $35.3M | XXX | $35.3M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 205.7x | XXX | -10.7x | XXX | XXX | XXX |
| EV/EBIT | -5.6x | XXX | -4.0x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.6x | XXX | -4.6x | XXX | XXX | XXX |
| EV/FCF | -5.2x | XXX | -5.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBRAIN Biotech's last 12 month revenue growth is 6%
BRAIN Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
BRAIN Biotech's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BRAIN Biotech's rule of X is 16% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BRAIN Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Growth | 1457% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BRAIN Biotech acquired XXX companies to date.
Last acquisition by BRAIN Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . BRAIN Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BRAIN Biotech founded? | BRAIN Biotech was founded in 1993. |
| Where is BRAIN Biotech headquartered? | BRAIN Biotech is headquartered in Germany. |
| How many employees does BRAIN Biotech have? | As of today, BRAIN Biotech has 307 employees. |
| Is BRAIN Biotech publicy listed? | Yes, BRAIN Biotech is a public company listed on ETR. |
| What is the stock symbol of BRAIN Biotech? | BRAIN Biotech trades under BNN ticker. |
| When did BRAIN Biotech go public? | BRAIN Biotech went public in 2016. |
| Who are competitors of BRAIN Biotech? | Similar companies to BRAIN Biotech include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of BRAIN Biotech? | BRAIN Biotech's current market cap is $51.5M |
| What is the current revenue of BRAIN Biotech? | BRAIN Biotech's last 12 months revenue is $62.6M. |
| What is the current revenue growth of BRAIN Biotech? | BRAIN Biotech revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of BRAIN Biotech? | Current revenue multiple of BRAIN Biotech is 0.6x. |
| Is BRAIN Biotech profitable? | Yes, BRAIN Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BRAIN Biotech? | BRAIN Biotech's last 12 months EBITDA is $0.2M. |
| What is BRAIN Biotech's EBITDA margin? | BRAIN Biotech's last 12 months EBITDA margin is 0%. |
| What is the current EV/EBITDA multiple of BRAIN Biotech? | Current EBITDA multiple of BRAIN Biotech is 205.7x. |
| What is the current FCF of BRAIN Biotech? | BRAIN Biotech's last 12 months FCF is -$6.7M. |
| What is BRAIN Biotech's FCF margin? | BRAIN Biotech's last 12 months FCF margin is -11%. |
| What is the current EV/FCF multiple of BRAIN Biotech? | Current FCF multiple of BRAIN Biotech is -5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
